SARS-CoV-2 3CLpro-IN-16 is a covalent SARS-CoV-2 3CLpro inhibitor that inhibits 3CLpro activity and achieves its inhibitory effect by forming a covalent bond with Cys145.

SARS-CoV-2 3CLpro-IN-15 (compound a), a beta-nitrostyrene derivative, acts as an inhibitor of the SARS-CoV-2 3CL protease (3CLpro), effectively inhibiting viral replication and transcription. It is instrumental in the identification of potential anti-COVID-19 lead compounds [1].

SARS-CoV-2 3CLpro-IN-20 is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM,).SARS-CoV-2 3CLpro-IN-20 has potential antiviral activity.

SARS-CoV-2 3CLpro-IN-19 (Compound C5a), a non-covalent, non-peptide inhibitor of the SARS-CoV-2 3CLpro enzyme, exhibits potent in vitro activity with an IC50 of 0.7 μM. It demonstrates broad-spectrum efficacy against infection by Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) in human cells, with EC50 values ranging from 30-69 nM [1].

SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active inhibitor of SARS-CoV-2 3CLpro, demonstrating potent anti-SARS-CoV-2 properties with an EC50 of 0.18 μM and exhibits minimal cytotoxicity, having a CC50 greater than 50 μM, in Vero E6 cells [1].

Compound 3h, also known as SARS-CoV-2 3CLpro-IN-17, is a selective inhibitor of the SARS-CoV-2 3CL protease, demonstrating an IC50 of 0.322 μM [1].

SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a multifunctional inhibitor of SARS CoV-2 3CLpro, exhibiting antiviral, antibacterial, and antifungal activities.

SARS-CoV-2 3CLpro-IN-10(5d) is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 190 nM, and demonstrates varied efficiency against other coronaviruses with IC50 values of 790 nM for SARS-CoV-1 and 70 nM for MERS-CoV, indicating broad-spectrum antiviral activity.

SARS-CoV-2 3CLpro-IN-2 is a potent inhibitor of the 3CL protease pair and has shown research potential for SARS-CoV-2 disease.

SARS-CoV-2 3CLpro-IN-11(11d) is a broad-spectrum antiviral compound that effectively inhibits the SARS-CoV-2 3CL protease, achieving an IC50 of 140 nM. Additionally, it exhibits inhibitory activity against SARS-CoV-1 and MERS-CoV with IC50 values of 240 nM and 70 nM, respectively.

SARS-CoV-2 3CLpro-IN-13 is a potent inhibitor of the SARS-CoV-2 3CL protease, demonstrating significant anti-coronavirus activity with an IC50 value of 21 nM [1].

SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a highly potent inhibitor specifically designed to target and inhibit the activity of SARS-CoV-2 3CL pro, which is a cysteine-protease found in the main coronaviruses. This particular enzyme has been recognized as a highly promising target for the development of effective antiviral drugs. Therefore, SARS-CoV-2 3CLpro-IN-1 holds significant potential for advancing research and development in the field of infectious diseases [1].

SARS-CoV-2 3CLpro-IN-21 (Compound D6) is an irreversible, covalent inhibitor of SARS-CoV-2 3CL pro, demonstrating potent inhibition with an IC50 of 0.03 μM. Additionally, it exhibits inhibitory activity against SARS-CoV-1 3CL pro with an IC50 of 0.12 μM [1].

SARS-CoV-2 3CLpro-IN-7 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an inhibitory concentration (IC50) value of 1.4 µM.

SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor targeting the SARS-CoV-2 3CL protease, demonstrating potent inhibitory activity with an IC50 of 4.9 μM. It is utilized in the research of coronavirus disease 2019 (COVID-19).

SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.478 μM. It demonstrates inhibition of SARS-CoV-2 in Vero E6 cells, with an EC50 of 2.499 μM, and exhibits low cytotoxicity (CC50 > 200 μM) [1].

SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), exhibiting potent inhibitory activity with an IC50 of 3.8 nM and demonstrating 9.0% oral bioavailability (BA). It is utilized in the research of coronavirus disease 2019 (COVID-19) [1].

SARS-CoV-2 3CLpro-IN-3 is a SARS CoV-2 3CLpro inhibitor that exhibits antiviral, antibacterial, and antifungal effects.

PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .

Boceprevir (SCH 503034) is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay.

SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, demonstrating IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme, 3CLpro, making it an attractive candidate for intervention strategies. SARS-CoV-2-IN-11 holds significant promise in the development of specific antivirals against SARS-CoV-2.

SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is a critical enzyme for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2.

Naldemedine tosylate (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) with high binding affinities (K_i = 0.34, 0.43, 0.94 nM) and potent antagonist activities (IC_50 = 25.57, 7.09, 16.1 nM) towards human recombinant μ-, δ-, and κ-opioid receptors, respectively. It is utilized in research on opioid-induced constipation (OIC). Additionally, Naldemedine tosylate is anticipated to interact with the 3CL proenzyme encoded by the SARS-CoV-2 genome.

Hydroxyethylamine (Compd VII) is a SARS-CoV-2 3CLpro inhibitor with an IC50 of ~10 μM in a transmission assay. hydroxyethylamine exhibits significant antiviral effects.

SARS-CoV-2-IN-6 is an inhibitor of SARS-CoV-2 3CLpro with the IC 50 value of 73 nM.

YH-53 is a potent 3CLpro inhibitor, exhibiting K i values of 6.3 nM and 34.7 nM against SARS-CoV-1 3CLpro and SARS-CoV-2 3CLpro, respectively. This peptidomimetic compound, characterized by its unique benzothiazolyl ketone structure, significantly inhibits SARS-CoV-2 replication, highlighting its potential in COVID-19 research [1] [2].

SARS-CoV-2-IN-41 (compound 2) is a potent inhibitor of SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.022 µM and demonstrating antiviral efficacy [1].

3CPLro-IN-1 (compound A17) is a potent, orally active inhibitor of SARS-CoV-2 3CLpro (IC50: 5.65 μM). 3-Chymotrypsin-like cysteine protease (3CLpro), a protein essential for viral replication, is an attractive drug target against COVID-19. Antitumor agent-51

GRL-0820 (SARS-CoV-2-IN-6) is a potent SARS-CoV-2 3CLpro inhibitor that can be used to study novel coronavirus infections.

Antcin-B exhibits a high-affinity inhibition of 3CLPro, which is potentially significant in SARS-CoV-2 research [1].

3CPLro-IN-2 is a potent, orally active inhibitor of SARS-CoV-2 3CLpro (IC50: 1.55 μM, Ki: 6.09 μM). 3-Chymotrypsin-like cysteine protease (3CLpro) is an essential protein for viral replication and is a potential drug target against COVID-19.

CCF0058981 (CCF981) is a 3-chlorophenyl analogue, serving as a noncovalent inhibitor of SARS-CoV-2 3CL pro (SC2), demonstrating potent activity with an IC50 of 68 nM. It also exhibits inhibitory effects against SARS-CoV-1 3CL pro (SC1) with an IC50 of 19 nM, highlighting its antiviral efficacy and potential in COVID-19 research [1].

PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.